Mid-term Oncologic Outcomes of Robot-assisted Radical Cystectomy: A Real-world Study.
Nov 12, 2026DOI: 10.1245/s10434-026-20695-0Journal ArticleASO
Written by: Kaiwen LiHao ChenTong SuTianxin LinJian Huang
BACKGROUND: Robot-assisted radical cystectomy (RARC) is increasingly prevalent. However, real-world data on its mid-term effectiveness in diverse patient populations remain limited.METHOD: We conducted a retrospective multicenter study of patients undergoing RARC for bladder cancer at 32 Chinese institutions (2012-2021). Baseline, perioperative, pathological, and survival data were collected. Missing data were handled by multiple imputation. Primary outcomes were overall survival (OS), recurrence-free survival (RFS), and cancer-specific survival (CSS). Multivariable Cox regression was used to identify independent prognostic factors.RESULTS: Among the 4395 enrolled patients, the median age was 65 years, and 85.1% were male. With a median follow-up of 26.6 months (interquartile range 12.7-47.6), the estimated 3-year OS, RFS, and CSS were 78.7%, 74.9%, and 81.7%, respectively. Multivariable analysis identified non-organ-confined disease (pT3-4) and lymph node metastasis as independent prognostic factors for worse OS, RFS, and CSS (all p<0.001). Adjuvant therapy was independently associated with worse RFS (hazard ratio 1.687; 95% confidence interval 1.389-2.049, p<0.001), and cutaneous ureterostomy was associated with worse RFS than ileal conduit (hazard ratio 1.241; 95% confidence interval 1.007-1.531, p=0.040).CONCLUSION: This large real-world study demonstrates that RARC provides satisfactory mid-term oncologic outcomes. Charlson Comorbidity Index, tumor stage, lymph node status, and urinary diversion choice significantly affect survival. These findings support the continued adoption of RARC and highlight the importance of patient selection and comprehensive perioperative management.